YOUR SEARCH FOR Text 42 RESULTS
21 of Total
Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… a status update on the Company’s development portfolio. “In the first quarter, we continued … for both tafasitamab and LIMBER this year.” Portfolio Update MPNs and GVHD – key highlights …
22 of Total
Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Offi
… strategy for the company and ensuring our portfolio decisions, business development and … therapeutics, Incyte has established a portfolio of first-in-class medicines for …
23 of Total
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… update on the Company’s clinical development portfolio. "The double-digit revenue growth in … therapeutics, Incyte has established a portfolio of first-in-class medicines for …
24 of Total
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance
… on the Company’s research and development portfolio. "We delivered a strong 2023 with … therapeutics, Incyte has established a portfolio of first-in-class medicines for …
25 of Total
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… update on the Company’s clinical development portfolio. "In the third quarter of 2024, we … therapeutics, Incyte has established a portfolio of first-in-class medicines for …
26 of Total
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Canc
… Congress and the data from Incyte’s oncology portfolio being featured at the meeting can be … therapeutics, Incyte has established a portfolio of first-in-class medicines for …
27 of Total
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… update on the Company’s clinical development portfolio. "We delivered a strong quarter with …
28 of Total
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… update on the Company’s clinical development portfolio. "Our double-digit revenue growth …
29 of Total
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance
… a number of key catalysts across the entire portfolio will bring that goal closer to … therapeutics, Incyte has established a portfolio of first-in-class medicines for …
30 of Total
Investors | Incyte
… Links Investor Presentation Responsibility News Portfolio Responsibility Report Annual Reports …